EcoR1 capital acquires $13.1 million in Zymeworks stock

EcoR1 Capital, LLC, a prominent investment firm, has significantly increased its stake in Zymeworks Inc . (NASDAQ:ZYME), acquiring shares worth approximately $13.1 million over the course of three days. This series of transactions, disclosed in a recent SEC filing, reflects EcoR1’s continued interest in the pharmaceutical company, which currently maintains a market capitalization of $872 million and holds more cash than debt on its balance sheet, according to InvestingPro data.

Between March 11 and March 13, EcoR1 purchased a total of 1,081,980 shares of Zymeworks’ common stock. The transactions were executed at prices ranging from $11.4935 to $12.4846 per share. Following these acquisitions, the firm now holds 16,802,141 shares in Zymeworks. The stock, which has gained nearly 17% over the past year, currently trades close to its InvestingPro Fair Value, with analysts setting price targets ranging from $12 to $30.

Oleg Nodelman, the manager and controlling owner of EcoR1, is a director of Zymeworks. Additionally, Scott Platshon, an employee of EcoR1, serves on the board of Zymeworks, having been nominated by EcoR1 and its affiliated funds.

These recent purchases highlight EcoR1’s strategic investment in the life sciences sector, particularly in companies like Zymeworks, which are focused on pharmaceutical preparations.

In other recent news, Zymeworks has reported a net loss of $122.7 million for the fiscal year 2024, translating to a loss of $1.62 per diluted share. The company’s revenue for the same period saw a marginal increase to $76.3 million from $76.0 million in 2023. Analysts from H.C. Wainwright noted that Zymeworks’ earnings fell short of expectations, leading to a wider-than-anticipated net loss. Despite this, the firm has a strong cash position of $324.2 million, expected to sustain operations into 2027.

In terms of stock evaluations, H.C. Wainwright raised Zymeworks’ price target to $13 while maintaining a Neutral rating. Meanwhile, Citi increased its price target to $19 and maintained a Buy rating, highlighting the company’s strategic financial decisions. Stifel also kept a Buy rating with a $28 price target, noting Zymeworks’ pipeline management decisions and the postponement of certain clinical trial data as potentially positive.

The company’s decision to prioritize the development of the GPC3-targeting ZW251 over ZW220 was noted by analysts as a strategic move to address high unmet medical needs in hepatocellular carcinoma. Furthermore, the launch of Zanodetimab by Jazz Pharmaceuticals (NASDAQ:JAZZ) is seen as a potential revenue stream for Zymeworks, adding to its future financial prospects.

This article was generated with the support of AI and reviewed by an editor. For more information see our T&C.